Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:60901
Name Waldenstroem's macroglobulinemia
Definition A lymphoplasmacytic lymphoma characterized by the accumulation of monoclonal cells in the bone marrow and peripheral lymphoid tissues, and associated with the production of serum immunoglobulin M (IgM) monoclonal protein.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma lymphoplasmacytic lymphoma Waldenstroem's macroglobulinemia

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02339922 Phase II Ixazomib + Rituximab Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT02457598 Phase I Entospletinib + Tirabrutinib Tirabrutinib Idelalisib + Obinutuzumab + Tirabrutinib Entospletinib + Obinutuzumab + Tirabrutinib Idelalisib + Tirabrutinib Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies Active, not recruiting USA | FRA 1
NCT02576496 Phase I Tinostamustine Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies Recruiting USA | ITA | FRA | ESP | DEU 2
NCT03085173 Phase I EGFRt/19-28z/4-1BBL CAR T cells A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies Active, not recruiting USA 0
NCT03147885 Phase Ib/II Selinexor Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT03162536 Phase I ARQ 531 Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies Active, not recruiting USA 0
NCT03364231 Phase II Umbralisib Study to Assess the Efficacy and Safety of Umbralisib in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma Completed USA 0
NCT03480360 Phase III Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Recruiting USA 0
NCT03498612 Phase II Pembrolizumab Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases Recruiting USA 0
NCT03557619 Phase I Ethinylestradiol + Levonorgestrel + Venetoclax A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Subjects With Different Hematological Malignancies Recruiting USA 1
NCT03630042 Phase II Pembrolizumab + Rituximab Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia (PembroWM) Recruiting 1
NCT03711578 Phase II Tenalisib Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K delta/gamma Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) Completed USA 1
NCT03740529 Phase Ib/II Cyclophosphamide + Doxorubicin + LOXO-305 + Prednisone + Rituximab + Vincristine Sulfate LOXO-305 + Rituximab + Venetoclax LOXO-305 + Venetoclax LOXO-305 A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL Recruiting USA | ITA | FRA 7
NCT03779113 Phase Ib/II HMPL-523 An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma Recruiting USA | ITA | ESP 2
NCT03786926 Phase Ib/II HMPL-689 Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas Recruiting USA | ITA | FRA | ESP 2
NCT03833180 Phase I VLS-101 A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies Recruiting USA 0
NCT03920631 Phase I Nivolumab Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ) Withdrawn USA 0
NCT04052854 Expanded access Zanubrutinib A Single-Arm, Expanded Access Study of Zanubrutinib (BGB3111) in Patients With B-cell Malignancies No longer available USA 0
NCT04061512 Phase II Cyclophosphamide + Dexamethasone + Rituximab Ibrutinib + Rituximab Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia (RAINBOW) Recruiting 1
NCT04115059 Phase I Dasatinib Dasatinib In Waldenstrom Macroglobulinemia Recruiting USA 0
NCT04260217 Phase I APG-2575 APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenstrom Macroglobulinemia (MAPLE-1) Recruiting USA 0
NCT04273139 Phase II Ibrutinib + Venetoclax Ibrutinib + Venetoclax in Untreated WM Active, not recruiting USA 0
NCT04274738 Phase I Ibrutinib + X4P-001 A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 Active, not recruiting USA 1
NCT04277637 Phase I BGB-11417 + Zanubrutinib BGB-11417 Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies Recruiting USA | ESP 2
NCT04540796 Phase I JNJ-75348780 A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Recruiting USA | FRA | ESP 5
NCT04624906 Phase II Acalabrutinib + Bendamustine + Rituximab Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia (BRAWM) Recruiting CAN 0
NCT04635683 Phase I Lenalidomide + Ublituximab + Umbralisib Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Suspended USA 0
NCT04665115 Phase II Ibrutinib Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) Withdrawn USA 0
NCT04728893 Phase II ARQ 531 Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies (MK-1026-003) Recruiting USA | ITA | FRA | ESP | CAN 7
NCT04830137 Phase I NX-2127 A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting USA 0
NCT04840602 Phase II Ibrutinib + Rituximab + Venetoclax Ibrutinib + Rituximab Testing the Addition of a New Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma Suspended USA 0
NCT04842877 Phase II DS-3201b Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma Recruiting FRA | BEL 0
NCT05065554 Phase II Acalabrutinib + Rituximab ACALA-R In Anti-MAG Neuropathy Mediated Neuropathy Recruiting USA 0
NCT05172700 Expanded access LOXO-305 Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer Available USA | DEU | BEL 4
NCT05256641 Phase Ib/II Acalabrutinib Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma Not yet recruiting USA 0